An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Ofatumumab (Primary) ; Bendamustine
- Indications B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; Novartis
- 25 Jun 2017 Results (n=32) presented at the 22nd Congress of the European Haematology Association.
- 25 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2015 Planned End Date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History